Berlin-Chemie Menarini
Corinna Templin is an accomplished professional in market access and pricing, currently serving as the Head of Market Access & Pricing at BERLIN-CHEMIE Menarini since August 2023. Prior to this role, Corinna held various positions at Novartis Oncology, starting as a Market Access Manager in January 2021. Corinna also contributed to Xcenda from July 2014 to December 2020, where responsibilities included Associate Director, Assistant Director, and Manager roles in Market Access. Earlier experience includes a position as Project Lead at the Niedersächsisches Landesgesundheitsamt from May 2012 to December 2013 and a Postdoctoral Research Assistant at Medizinische Hochschule Hannover from July 2010 to March 2012. Corinna commenced a research assistant internship at the Federal Ministry of Health in 2011. Academic qualifications include a Master of Public Health focused on Epidemiology and Health Economics from Hannover Medical School, a Dr. rer. nat. in Virology from Hannover Medical School, and a Diplom in Biology from Technische Universität Braunschweig.
This person is not in any offices
Berlin-Chemie Menarini
1 followers
BERLIN-CHEMIE is an international research-based pharmaceutical company with its headquarters in Berlin, Germany. The company has subsidiaries in over 30 countries in Europe and Asia. In 2022, BERLIN-CHEMIE employed around 5,000 people worldwide and achieved sales of €1.5 billion. Since 1992 BERLIN-CHEMIE has been part of the Italian Menarini Group, a leading global family-owned pharmaceutical and diagnostics company with a presence in over 140 countries. The group's global reach extends across Europe, Central America, Africa, the Middle East and Asia and generates annual sales of over € 4.155 billion. For over 125 years Menarini has invested in the development and commercial distribution of pharmaceuticals in order to offer patients and doctors around the world a wide portfolio of products in the fields of cardiovascular, respiratory, gastroenterology, metabolism, infectious diseases and anti-inflammatory/analgesic therapies. Menarini is also heavily involved in the field of oncology, where several new molecules for the treatment of a wide range of tumours are currently under development. Within the Menarini Group, BERLIN-CHEMIE is responsible for the pharmaceutical business in Germany, Eastern Europe and the CIS region. In addition, Berlin hosts one of the Group’s central research and development sites. Are you interested in working with us? Discover all available positions with just one click on our Careers Portal: careers.berlin-chemie.de Netiquette & Privacy Notice: https://www.berlin-chemie.de/social-media-datenschutz-und-netiquette Imprint: www.berlin-chemie.com/imprint This profile is maintained by the Communication & Public Relations department.